TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -8.7% ·
share flow -0.7% ·
net new positions -9.5%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +3 | 260.72M | $131.51B | +5 | −1 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | — |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | — |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | — | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | — |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | — | −2 |
| Q2 2024 | 23 | — | 44.78M | $24.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 10.97M | +10.6% | $6.79B | 0.8% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Capital World Investors ✦ | 9.33M | -2.0% | $5.77B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 7.66M | +1.7% | $4.72B | 0.4% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 5.59M | +0.4% | $3.46B | 0.5% | ▲ Add | 2 | SEC ↗ |
| 5 | Fisher Asset Management ✦ | 2.64M | +2.5% | $1.63B | 0.7% | ▲ Add | 2 | SEC ↗ |
| 6 | PRIMECAP Management ✦ | 2.57M | -3.5% | $1.59B | 1.2% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 2.53M | -16.4% | $1.56B | 0.3% | ▼ Trim | 2 | SEC ↗ ×8 |
| 8 | Marshall Wace ✦ | 627.73K | +89576.1% | $388.30M | 0.5% | ▲ Add | 2 | SEC ↗ ×3 |
| 9 | Baillie Gifford ✦ | 603.39K | -2.9% | $373.24M | 0.3% | ▼ Trim | 2 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 397.23K | -7.2% | $245.71M | 0.6% | ▼ Trim | 2 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 357.72K | +1.6% | $221.28M | 0.4% | ▲ Add | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 337.85K | +67.9% | $208.98M | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 211.41K | +115.4% | $129.35M | 0.2% | ▲ Add | 2 | SEC ↗ ×4 |
| 14 | Arrowstreet Capital ✦ | 206.32K | +588.9% | $127.63M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 166.19K | -83.1% | $102.80M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 16 | Millennium Management ✦ | 122.48K | -78.3% | $75.76M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 48.95K | -79.2% | $30.28M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Markel Group ✦ | 35.40K | +20.4% | $21.90M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 19 | Dodge & Cox ✦ | 26.77K | -0.1% | $16.56M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 23.41K | +10.0% | $14.48M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 21 | GAMCO Investors ✦ | 4.28K | -0.2% | $2.65M | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $186.10M | was 0.6% |
| Bridgewater Associates | $18.65M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $11,944 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.73K sh · $2.29M
Officer · 400 sh · $245,752
Officer, Director · 62 sh · $38,982
Officer, Director · 33 sh · $20,677
Officer, Director · 101 sh · $63,166
Officer, Director · 79 sh · $49,613
Officer, Director · 2.15K sh · $1.35M
Officer, Director · 1.79K sh · $1.12M
Officer, Director · 3.01K sh · $1.89M
Officer, Director · 2.73K sh · $1.71M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology